TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Langerhans cell histiocytosis (LCH) by demonstration of CD1a positivity or Birbeck granules in lesions~* Considered poor-risk, defined as multisystem disease with involvement of one or more risk organs (i.e., liver, spleen, lungs, and/or hematopoietic system)~  * No isolated lung only LCH~* Progressive disease after one of the following treatments:~  * LCH-III protocol or other standard LCH-directed therapies~ * At least 1 course of the current salvage protocol (i.e., LCH-2 2005) or similar therapy (e.g., cytosine arabinoside or cladribine-based regimens)~* HLA-matched related or unrelated donor OR unrelated umbilical cord blood (UCB) available~  * 1 locus mismatch for donor allowed~ * Up to 2 loci mismatch for unrelated UCB allowed~* Any hematologic status (transfusion support allowed)~* Adequate hepatic, renal, cardiac, and pulmonary function to undergo reduced-intensity hematopoietic cell transplantation (RI-HCT) including the following:~  * Transaminases \< 5 times upper limit of normal (ULN)~ * Bilirubin \< 3 times ULN (unless secondary to hepatic LCH)~ * Creatinine ≤ 2 mg/dL (adults) (if creatinine \> 1.2 OR history of renal dysfunction, must have estimated creatinine clearance \> 40 mL/min)~ * Creatinine clearance \> 40 mL/min (pediatrics)~ * Glomerular filtration rate ≥ 50mL/min~* Negative pregnancy test~Exclusion Criteria:~* Decompensated congestive heart failure, uncontrolled arrhythmia, or left ventricular ejection fraction ≥ 35%~* Pulmonary failure (i.e., requiring mechanical ventilation) unless secondary to active underlying LCH~* Isolated liver sclerosis or pulmonary fibrosis unless secondary to active underlying LCH~* Uncontrolled active life-threatening infection~* Pregnant or nursing~* Less than 4 weeks after last attempted salvage chemotherapy treatment~* Other concurrent chemotherapy agents (e.g., methotrexate) during entire transplantation period up to day 100 post-transplantation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab (Type: EXPERIMENTAL): Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Valproate in Peripheral Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* peripheral neuropathic pain~* signed written informed consent~Exclusion Criteria:~* central neuropathic pain~* current or past hepatic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Visualizing Beta Cells After Islet Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Tx-group:~* \>18 years old~* T1D patient undergone islet transplantation~* Clinically proven functional islet graft~* Signed informed consent~Control group:~* \>18 years old~* T1D patients who are on the waiting list for islet transplantation~* Signed informed consent~Exclusion Criteria:~* Treatment with synthetic exendin or Dipeptidyl-Peptidase IV inhibitors within the last 3 months~* Breast feeding~* Pregnancy or the wish to become pregnant within 6 months~* Kidney disease~* Liver disease~* Age \<18 years~* No signed informed consent~Exclusion criteria for MR:~* fragments, clips or devices in brain, eyes, spinal canal~* Implantable defibrillator or pacemaker (wires)~* Mandibular magnetic implants~* Neurostimulator, bladder stimulator, non-removable insulin pump~* Metal tissue-expander in chest~* Cochlear implant~* Ossicular replacement prosthesis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Tx-group (Type: None): T1D patients that received islet of Langerhans transplantation (Tx) at least 3 months earlier
- Control group (Type: None): T1D patients that await islet of Langerhans transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: An Assessment of Voriconazole Pharmacokinetics and Pharmacogenetics in Liver Transplant Recipients - Pilot Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Consecutive male or female liver transplant recipients, 18 years old, who are initiated on the voriconazole prophylactic regimen by their transplant physician as part of their standard care, will be eligible for inclusion in the study.~Exclusion Criteria:~* Transplant recipients receiving voriconazole to treat an active fungal infection will be excluded. Transplant recipients that are concurrently receiving medications that are documented to affect voriconazole pharmacokinetics will be excluded. The agents included, but may not be limited to the following; carbamazepine, phenytoin, omeprazole, rifabutin, rifampin, ketoconazole, itraconazole, fluconazole, St. John's wort extract. Those who require therapy with protease inhibitors for human immunodeficiency virus (HIV) infection may be included in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent obtained by parents/legal representative(according to local regulation) prior to or after birth.~2. Birth weight ≥ 3rd centile for gestational age (GA), according to the Centers for Disease Control and Prevention (CDC) growth chart~3. Gestational age ≥ 36 weeks~4. Exposure to opioids during the last month of fetal life~5. Signs of neonatal opioid withdrawal syndrome requiring treatment, and the sum of 3 consecutive FNAST scores is ≥ 24 or a single score ≥ 12~Exclusion Criteria:~1. Familial history of prolonged QTc syndrome~2. Major congenital malformations or evidence of congenital infection~3. Signs of fetal alcohol spectrum disorders~4. Maternal alcohol abuse, defined as average of 3 or more drinks per week in the last 30 days~5. Medical illness at the time of randomization, including but not exclusively:~   1. Neonatal hypoglycemia requiring intravenous glucose therapy~  2. Neonatal respiratory illness requiring non-invasive or invasive respiratory support~  3. Neonatal encephalopathy (including hypoxic ischemic encephalopathy or seizures~  4. Severe hyperbilirubinemia-bilirubin at or above the exchange transfusion threshold as defined by the American Academy of Pediatrics (AAP)~  5. Severe elevation of serum aminotransferases (more than twice the upper limit of the age appropriate aminotransferases reference range of the investigational site).~  6. Proven or suspected early onset neonatal infection which will require more than 48 hours treatment with antibiotics~6. Unable to tolerate an oral or sublingual medication~7. Need for medications forbidden in this study protocol~8. Any condition that, in the opinion of the Investigator, would place the neonate at undue risk~9. Participation in another clinical trial of any medicinal product, placebo, experimental medical device or biological substance conducted under the provisions of a protocol on the same therapeutic target. The participation in studies involving diagnostic devices or treatments for conditions other than NOWS and Neonatal abstinence syndrome (NAS) may be permitted following an agreement with the Sponsor. Non-interventional observational studies are allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Days
- Healthy Volunteers: f

Study Arms:
- CHF6563 (Type: EXPERIMENTAL): Sublingual dose of CHF6563 and the corresponding oral dose of morphine matched placebo
- Morphine (Type: ACTIVE_COMPARATOR): Oral dose of morphine and the corresponding sublingual dose of CHF6563 matched placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provide signed and dated informed consent form~* Willing to comply with all study procedures and be available for the duration of the study~* Male or female, aged 50-80~* In sufficiently good general health to be able to have a FFA~* CNV diagnosed by OCT~* Vision equal or better than 6/60 in the study eye~* No prior treatment in the study eye with anti-VEGF medication~Exclusion Criteria~* Significant media opacity.~* Known allergic reactions to components of the study product(s).~* Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Naive wet age-related macular degeneration (Type: None): Patients recruited to the study will be patients who meet the Australian MBS criteria for treatment of exudative CNV with Lucentis. For the duration of the study, the patients will have standard induction and monthly dosing of Lucentis (Ranibizumab; intravitreal; 0.5 mg) to allow comparison with published studies. The only extra intervention for the study is the acquisition of hyperspectral mages with the hyperspectral camera and the acquisition of additional fundus autofluorescence images to the clinical norm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Whole Brain Radiotherapy (WBRT) Versus Stereotactic Radiosurgery (SRS) for 4 Upto 10 Brain Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Minimal 4 up to a maximum of 10 BM on diagnostic MRI scan~* Max diameter of single GTV 2.5cm~* Max cumulative GTV of 30cm3~* Karnofsky performance status ≥ 70~* Any solid primary tumour. Small cell lung carcinoma, germinoma, and lymphoma are excluded~* Ability to provide written informed consent~Exclusion Criteria:~* Contra-indication for MRI~* Prior treatment for BM (i.e. surgery, SRS or WBRT)~* Concurrent use of systemic therapy~* Maximum cumulative GTV of more than 30cm3 on planning-MRI~* More than 10 BM on planning-MRI~* A brainstem metastasis with a PTV of more than 20 cm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stereotactic Radiosurgery (Type: EXPERIMENTAL): Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases:
- Whole Brain Radiotherapy (Type: OTHER): Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases:

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \</= 70 years~* Documented myeloma confirmed at protocol entry~* Adequate presence of \>/=2.0x10e6/kg cryopreserved CD34+ cells~* Adequate organ function~* Prior therapy is allowed as long as the organ function parameters are maintained and/or excessive radiation exposure is not produced~* Chemosensitivity~Exclusion Criteria:~* Uncontrolled infection~* Pregnant or lactating females~* Patients in \>/= very good partial response after initial primary non-transplant therapy and/or AHSCT1~* Patients unwilling to practice adequate forms of contraception if clinically indicated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Total Skeletal Irradiation (Type: EXPERIMENTAL): Three subjects determined to be eligible for study and agree to participate are assigned to receive 200 cGy of TSI-HT for 5 days. If this dose level is well tolerated in the first 3 subjects, the dose will be increased and given over 5 days. The dose will continue to be increased until the maximum toelrated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Hazardous duty in Iraq or Afghanistan with the US Armed Forces during Operations Iraqi Freedom and Operation Enduring Freedom~* Exposure to at least a moderate level of combat (\>5 on Revised Combat Exposure Scale)~* Good general medical health~* Stable dose of non-excluded medications for at least 4 weeks prior to randomization~* \>5 on CAPS recurrent distressing dreams item~* \>5 on CAPS difficulty falling or staying asleep item~Exclusion Criteria:~* Acute or significant chronic medical illness, preexisting hypotension or orthostatic hypotension, pancreatitis, gout, Ménière's disease, benign positional vertigo, narcolepsy, or any other unstable medical condition.~* Women of childbearing potential with either positive pregnancy test or refusal to use effective birth control method will be excluded.~* Lifetime schizophrenia, schizoaffective disorder, bipolar disorder, psychotic disorder or any Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) cognitive disorder, current delirium, substance dependence disorder within 3 months of the study, severe psychiatric instability or severe situational life crises, including evidence of being actively suicidal or homicidal, or any behavior which poses an immediate danger to patient or others.~* Allergy or previous adverse reaction to prazosin or other alpha-1 antagonist or paroxetine or any other SSRI, no concurrent use of another alpha-1 antagonist agent, no concurrent use of an antidepressant (other than trazodone prescribed for sleep).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Prazosin
- 2 (Type: ACTIVE_COMPARATOR): Paroxetine
- 3 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Joint Pain in Patients With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Plaque psoriasis~* Pain from at least two peripheral joints and/or inflammatory back pain~* No or stabile treatment of the psoriasis the last 3 months~* No or stabile pain treatment the last 3 months~* Oral and written information given~* Written consent signed~Exclusion Criteria:~* Arthritis with Ultrasound verified intra articular fluid og clinical verified joint swelling~* Pregnancy og breastfeeding~* Previous treatments with acupuncture~* Treatment with anticoagulants (vitamin K-antagonists, low molecular weight heparin, unfractionated heparin, direct thrombin inhibitors, direct factor Xa inhibitors)~* Unwilling to follow protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acupuncture in active points (Type: ACTIVE_COMPARATOR): Patients in this group will receive real acupuncture
- Acupuncture in non-active points (Type: SHAM_COMPARATOR): Patients in this group will receive acupuncture, but in non-active points
- No treatment, just observation (Type: NO_INTERVENTION): Patients in this group will receive no treatment and will only be observed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed diagnosis of Estrogen Receptor (ER) positive and HER2 (human epidermal growth factor receptor 2) positive metastatic breast cancer based on local laboratory results.~* Prior treatment with a taxane (including paclitaxel, docetaxel and/or nanoparticle protein-bound paclitaxel).~* Prior treatment with trastuzumab with or without pertuzumab.~* Measurable or non-measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1.~* Eastern Cooperative Oncology Group Performance Status of 0-2~* Adequate organ and marrow function~* Women must be post-menopausal~* Must be able to swallow pills~Exclusion Criteria:~* Current or anticipated use of other investigational agents~* Prior therapy with a cyclin-dependent kinase 4/6 inhibitor~* Subject has received chemotherapy or radiotherapy within 14 days prior to Cycle 1, Day 1 of the study or has not recovered from adverse events due to agents administered more than 14 days earlier~* Subject has leptomeningeal disease~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib or other agents used in study~* Subject has other illness or disease that the investigator believes will interfere with study requirements.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1: Palbociclib 75 mg (Type: EXPERIMENTAL): Palbociclib 75 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
- Phase 1: Palbociclib 100 mg (Type: EXPERIMENTAL): Palbociclib 100 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
- Phase 1: Palbociclib 125 mg (Type: EXPERIMENTAL): Palbociclib 125 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
- Phase 2: RP2D (Type: EXPERIMENTAL): Recommended Phase 2 dose (RP2D; determined during Phase 1 Safety Run In) Palbociclib by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glucose Control In Hematopoetic Stem Cell Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18~* Must meet standard criteria for HSCT~* If patient is known diabetic at admit the may be maintained on home sulfonylurea and insulin if randomized to the conventional arm~Exclusion Criteria:~* If on intensive arm patient must stop all oral hyperglycemic meds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Regular Sliding Scale Insulin administration for hyperglycemia
- Arm 2 (Type: EXPERIMENTAL): MiniMed Paradigm monitoring device for hyperglycemia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues